Tag: Innovent Biologics
Innovent Biologics showcases promising preclinical data at AACR 2024
In a significant development for cancer research, Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company renowned for its innovative medicines in oncology, cardiovascular and ... Read More
Innovent Biologics announces positive Phase 2 results for Efdamrofusp Alfa in nAMD
In an important development for the treatment of neovascular age-related macular degeneration (nAMD), Innovent Biologics, Inc., a leading biopharmaceutical company, has announced successful results from ... Read More
RemeGen, Innovent Biologics to collaborate on clinical trials for combination therapies with ADCs
RemeGen, a commercial-stage Chinese biotechnology firm, and Innovent Biologics have announced their collaboration in a clinical research and supply agreement. This partnership focuses on conducting ... Read More
Innovent Biologics’ olverembatinib gets Chinese breakthrough therapy status in SDH-deficient GIST
Innovent Biologics has been granted breakthrough therapy designation (BTD) for olverembatinib from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). ... Read More
Innovent Biologics, Sanofi to expedite development of cancer drugs in China
Chinese biopharma company Innovent Biologics and French pharma giant Sanofi have entered into a partnership that aims to bring innovative drugs to patients in China ... Read More
FDA rejects Lilly’s sintilimab as first line treatment of NSCLC
The US Food and Drug Administration (FDA) has rejected the biologics license application (BLA) of Eli Lilly and Company (Lilly)’s sintilimab injection in nonsquamous non-small ... Read More
Lilly, Innovent Biologics expand licensing deal for blood cancer drug Tyvyt
Eli Lilly and Company has signed an expanded licensing deal worth up to $1 billion with Chinese biotech company Innovent Biologics for their jointly developed ... Read More
Innovent Biologics begins parsaclisib phase 2 trial in follicular lymphoma
Innovent Biologics has dosed the first patient in a phase 2 trial of parsaclisib (IBI-376), a novel and selective PI3Kδ inhibitor in follicular lymphoma (FL). ... Read More
Incyte secures FDA priority review for pemigatinib in cholangiocarcinoma
Delaware-based pharma company Incyte has secured priority review for pemigatinib from the US Food and Drug Administration (FDA) for the treatment of locally advanced or ... Read More
Innovent Biologics begins phase 1 trial of IBI315 in solid malignancies
Innovent Biologics and Beijing Hanmi Pharmaceutical, a subsidiary of Hanmi Pharmaceutical, said that the first patient has been dosed in a phase 1 clinical trial ... Read More